| Detected | Trial | Change |
|---|---|---|
| 2026-08-09 | NCT06163430 A Phase 1/2 Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and… · Terns, Inc. |
Sponsor changed: Terns, Inc. -> Terns, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) |
| 2026-08-09 | NCT02061800 CD34+ (Malignant) Stem Cell Selection for Patients Receiving Allogenic Stem Cell… · Diane George |
overall status: Active, Not Recruiting → Unknown |
| 2026-08-08 | NCT07269470 Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With… · M.D. Anderson Cancer Center |
Recruitment opened |
| 2026-08-08 | NCT05092451 Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in… · M.D. Anderson Cancer Center |
date change Primary completion pushed: 2026-08-31 -> 2030-08-31 |
| 2026-08-08 | NCT05092451 Phase I/II Study of CAR.70- Engineered IL15-transduced Cord Blood-derived NK Cells in… · M.D. Anderson Cancer Center |
date change Completion pushed: 2026-08-31 -> 2030-08-31 |
| 2026-07-29 | NCT05362773 A Study of MGD024 in Patients With Relapsed or Refractory Hematologic Malignancies · MacroGenics |
Enrollment closed, study ongoing |
| 2026-07-23 | NCT03849651 TCRαβ-depleted Progenitor Cell Graft With Additional Memory T-cell DLI, Plus Selected Use… · St. Jude Children's Research Hospital |
date change Completion pushed: 2026-06-07 -> 2027-12-31 |
| 2026-07-23 | NCT05143840 Asciminib as Initial Therapy for Patients With Chronic Myeloid Leukemia in Chronic Phase · University of Alabama at Birmingham |
overall status: Recruiting → Active, Not Recruiting |
| 2026-07-21 | NCT05589896 A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased… · Ossium Health, Inc. |
overall status: Recruiting → Active, Not Recruiting |
| 2026-07-21 | NCT05589896 A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased… · Ossium Health, Inc. |
date change Primary completion pushed: 2026-05-31 -> 2026-07-14 |
| 2026-07-21 | NCT05589896 A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased… · Ossium Health, Inc. |
date change Completion pushed: 2027-03-31 -> 2029-05-31 |
| 2026-07-19 | NCT07166419 Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the… · Ohio State University Comprehensive Cancer Center |
critical Recruitment suspended |
| 2026-07-19 | NCT07166419 Anti-CD19/20/22 Chimeric Antigen Receptor T Cells (TriCAR19.20.22 T Cells) for the… · Ohio State University Comprehensive Cancer Center |
critical why stopped: — → On hold for review |
| 2026-07-19 | NCT03480360 Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune… · Dartmouth-Hitchcock Medical Center |
Trial completed |
| 2026-07-19 | NCT03480360 Haploidentical Allogeneic Peripheral Blood Transplantation: Examining Checkpoint Immune… · Dartmouth-Hitchcock Medical Center |
date change Completion moved earlier: 2026-10-17 -> 2025-10-17 |
| First Posted | Trial | Sponsor | Phase |
|---|---|---|---|
| 2026-08-11 | NCT07758218 Allogeneic iNKT Cell Therapy (agenT-797) After SCT | University of Wisconsin, Madison NEW | Phase 1 |
| 2026-07-31 | NCT07740603 Study of CD38 and CD56 in Chronic Myeloid Leukemia | Sohag University NEW | |
| 2026-06-16 | NCT07651878 Phase I Trial of Vididencel in CML-CP Patients With MRD Under TKI Treatment | Mendus NEW | Phase 1 |
| 2026-06-11 | NCT07640750 Efficacy of Asciminib in Real-world in Patients With Chronic Myeloid Leukemia in Second… | Gruppo Italiano Malattie EMatologiche dell'Adulto NEW | |
| 2026-06-10 | NCT07638007 Impact of Targeted Therapy on Cancer-Related Cognitive Impairment | University of Rochester NCORP Research Base NEW |
| NCT ID | Title | Sponsor | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT05367765 | A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients… | Jiangsu Hansoh Pharmaceutical Co., Ltd. | Not Yet Recruiting |
| Phase 3 | |||
| NCT03459534 | A Phase 3 Study for the Efficacy and Safety of Radotinib in CP-CML Patients With Failure… | Il-Yang Pharm. Co., Ltd. | Recruiting |
| NCT06423911 | Study of Olverembatinib (HQP1351) in Patients With CP-CML | Ascentage Pharma Group Inc. | Recruiting |
| NCT03722420 | Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With… | Il-Yang Pharm. Co., Ltd. | Active, Not Recruiting |
| NCT05753384 | Discontinuation of TyrosIne Kinase Inhibitors (TKI) in Chronic Myeloid Leukemia (CML) and… | Poitiers University Hospital | Active, Not Recruiting |
| NCT05456191 | A Study to Investigate Tolerability and Efficacy of Asciminib (Oral) Versus Nilotinib… | Novartis Pharmaceuticals | Active, Not Recruiting |
| NCT04971226 | A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+… | Novartis Pharmaceuticals | Active, Not Recruiting |
| Phase 2 | |||
| NCT03852407 | Allogeneic Hematopoietic Cell Transplantation From HLA-matched Donor After Flu-Mel-PTCy… | University of Liege | Recruiting |
| NCT06508099 | Vitamin A and D Supplementation in Allogeneic HCT | St. Petersburg State Pavlov Medical University | Recruiting |
| NCT06532084 | Sorafenib Relapase Prophylaxis After HCT With PTBCy Regimen | St. Petersburg State Pavlov Medical University | Recruiting |
| NCT06453902 | TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) Patients | Shenzhen TargetRx Co., Ltd. | Recruiting |
| NCT06355583 | Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) Trial | Imperial College London | Recruiting |
| NCT06409936 | PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML | Gruppo Italiano Malattie EMatologiche dell'Adulto | Recruiting |
| NCT05884333 | Cord Blood Transplant in Adults With Blood Cancers | Memorial Sloan Kettering Cancer Center | Recruiting |
| NCT05031897 | Two Step Haplo With Radiation Conditioning | Thomas Jefferson University | Recruiting |
| NCT07238712 | Optimization of Post-transplantation Benadamustine and Cyclophosphamide in Patients With… | St. Petersburg State Pavlov Medical University | Recruiting |
| NCT06059391 | CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of… | City of Hope Medical Center | Recruiting |
| NCT06859424 | A Platform Protocol to Investigate Post-Transplant Cyclophosphamide-Based… | Center for International Blood and Marrow Transplant Research | Recruiting |
| NCT06368414 | A Study of Treatment-free Remission in Chronic Phase Chronic Myeloid Leukemia | Korean Society of Hematology | Recruiting |
| NCT06514534 | Open-label Study of Asciminib for CML-CP or CML-AP Patients With T315I Mutation Who Are… | Novartis Pharmaceuticals | Recruiting |
| NCT06817720 | Phase II Study Assessing the Efficacy and Toxicity of Olverembatinib Monotherapy in… | M.D. Anderson Cancer Center | Recruiting |
| NCT04195633 | Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for… | Fred Hutchinson Cancer Center | Recruiting |
| NCT05800210 | Alpha/Beta T Cell and CD19+ B Cell Depletion in Allogeneic Stem Cell Transplantation in… | University of Florida | Recruiting |
| NCT06802315 | Intensity Modulated Total Marrow Irradiation in Fully Human Leukocyte Antigen… | University of Illinois at Chicago | Recruiting |
| NCT02889003 | Second STOP After Pioglitazone Priming in CML Patients | Versailles Hospital | Recruiting |